Karen Akinsanya, President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships, on September 17, 2026, sold 31,599 shares in Schrodinger (SDGR) for $927,970. Following the Form 4 filing with the SEC, Akinsanya has control over a total of 69,956 common shares of the company, with 69,956 shares held directly.
SEC Filing:
Joseph Baratta, Director, on September 18, 2026, sold 100,000 shares in Blackstone (BX) for $12,380,048. Following the Form 4 filing with the SEC, Baratta has control over a total of 771,599 common shares of the company, with 771,599 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1393818/000119312526395751/xslF345X05/ownership.xml
Anthony Mathew Eisen, Director, on September 16, 2026, sold 18,000 shares in Block (XYZ) for $1,397,280. Following the Form 4 filing with the SEC, Eisen has control over a total of 1,380,672 Class A common shares of the company, with 1,380,672 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1512673/000162828026062773/xslF345X05/wk-form4_1789766805.xml
Colette Kress, Executive Vice President & Chief Financial Officer, on September 16, 2026, sold 34,918 shares in Nvidia (NVDA) for $7,648,632. Following the Form 4 filing with the SEC, Kress has control over a total of 4,775,733 common shares of the company, with 765,103 shares held directly and 4,010,630 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1045810/000158867026000014/xslF345X05/wk-form4_1789765959.xml